Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by 68Ga-DOTANOC PET/CT: Two Cases

Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to trea...

Full description

Saved in:
Bibliographic Details
Published in:World journal of oncology 2014-04, Vol.5 (2), p.72-76
Main Authors: Savelli, Giordano, Muni, Alfredo, Barbieri, Roberto, Valmadre, Giuseppe, Biasiotto, Giorgio, Minari, Chiara, Ghimenton, Claudio, Pagani, Renato, Pecini, Elisa, Falcone, Matteo
Format: Article
Language:English
Subjects:
Case Report
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to treatment and evolve toward a more aggressive type of cancer. This clinical entity, named castration-resistant prostate cancer, has few and less effective therapeutic opportunities. Therefore, any additional information concerning possible biological targets to therapy is welcome. Here we describe two cases in which 68 Ga-DOTANOC PET/CT evidenced the somatostatin receptor overexpression by prostate metastases. The presence of these receptors may support with a more strong evidence the possibility to administer somatostatin analogs as an adjuvant therapy.
ISSN:1920-4531
1920-454X
DOI:10.14740/wjon739w